ISO/TR 22442-4:2010-12 (E)

Medical devices utilizing animal tissues and their derivatives - Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes

Contents

Page

Foreword iv

Introduction v

1 Scope 1

2 Normative references 1

3 Terms and definitions 2

4 Elimination of TSE agents: basic considerations 2
4.1 General 2
4.1.1 TSEs of concern 2
4.1.2 Animal tissues of concern 2
4.1.3 Tissues infected with TSE agents 2

5 Potential methods to eliminate TSE agents 3
5.1 Methods for inactivating infectivity 3
5.1.1 General 3
5.1.2 Physical methods for inactivating TSE infectivity 3
5.1.3 Chemical methods for inactivating TSE infectivity 4
5.2 Methods for removing TSE infectivity without inactivating infectivity 5

6 Experimental validation of methods for eliminating TSE agents from medical devices utilizing non-viable animal tissues 6
6.1 General 6
6.2 Defining of product families for purposes of designing TSE process validation studies 6
6.3 Selection and testing of product for establishing and verifying the infecting dose of TSE agent 6
6.4 TSE agent spiking materials 6
6.5 Availability of bioassay animals (conventional and transgenic mice, other rodents, farm animals) 7
6.6 Potential development of cell culture assays for infectivity 7
6.7 Correlations between PrPTSE and infectivity assays 7
6.8 Reductions in infectivity compared with failure to detect at limits of detection 8
6.9 Determining numbers of replicate validations needed to support inferences of reduction in infectivity rather than variations in assay performance 8
6.10 Requirements for step-wise reductions in PrPTSE and infectivity verses whole-process validation 8

Bibliography 9